Carrie Bourdow
Chief Executive Officer en TREVENA, INC. .
Fortuna: 43 442 $ al 31/03/2024
Perfil
Carrie L.
Bourdow is currently the Chairman, President & Chief Executive Officer at Trevena, Inc. She previously served as an Independent Director at Sesen Bio, Inc. from 2020 to 2023 and at Nabriva Therapeutics Plc from 2017 to 2023.
Prior to that, she was the Vice President-Marketing at Cubist Pharmaceuticals LLC from 2013 to 2015.
Ms. Bourdow holds an undergraduate degree from Hendrix College and an MBA from Southern Illinois University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
TREVENA, INC.
0.51% | 09/02/2024 | 93 214 ( 0.51% ) | 42 878 $ | 31/03/2024 |
NABRIVA THERAPEUTICS PLC
0.01% | 31/01/2023 | 397 ( 0.01% ) | 564 $ | 31/07/2023 |
Cargos activos de Carrie Bourdow
| Empresas | Cargo | Inicio |
|---|---|---|
| TREVENA, INC. | Chief Executive Officer | 01/10/2018 |
Antiguos cargos conocidos de Carrie Bourdow.
| Empresas | Cargo | Fin |
|---|---|---|
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 30/07/2023 |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 07/03/2023 |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01/05/2015 |
Formación de Carrie Bourdow.
| Hendrix College | Undergraduate Degree |
| Southern Illinois University | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| TREVENA, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Empresas privadas | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Carrie Bourdow
